|
Market Closed -
Nasdaq
20:00:00 13/03/2026 GMT
|
5-day change
|
1st Jan Change
|
|
536.12 USD
|
+0.62%
|
 |
+12.12%
|
+10.03%
|
|
03-11 |
United Therapeutics Corporation Publishes Full Results Of TETON-2 Phase 3 Clinical Trial For Tyvaso Inhalation Solution
|
CI
| |
03-09 |
BETA Technologies Participates In FAA?s eVTOL Integration Pilot Program Across 10 States
|
CI
| |
03-09 |
United Therapeutics Corporation authorizes a Buyback Plan.
|
CI
| |
03-09 |
United Therapeutics Corporation announces an Equity Buyback for $2,000 million worth of its shares.
|
CI
| |
03-09 |
United Therapeutics unveils $2 bln buyback plan, launches $1.5 bln accelerated repurchase
|
RE
| |
03-02 |
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
|
CI
| |
03-02 |
United Therapeutics' drug slows progression of rare lung condition in late-stage study
|
RE
| |
03-02 |
United Therapeutics' blood pressure drug meets main, secondary goals in late-stage study
|
RE
| |
02-26 |
United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says
|
MT
| |
02-25 |
United Therapeutics Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
|
CI
| |
02-25 |
Stocks Rise Pre-Bell Ahead of Nvidia's Latest Quarterly Results
|
MT
| |
02-25 |
United Therapeutics Q4 Earnings, Revenue Increase
|
MT
| |
02-25 |
Earnings Flash (UTHR) United Therapeutics Corporation Reports Q4 Revenue $790.2M, vs. FactSet Est of $811.4M
|
MT
| |
02-25 |
Earnings Flash (UTHR) United Therapeutics Posts Q4 EPS $7.70, vs. FactSet Est of $6.67
|
MT
| |
01-26 |
United Therapeutics Corporation Announces Positive Results from Phase 1 Study of MiroliverELAP® in Patients with Acute Liver Failure
|
CI
| |
11-12 |
United Therapeutics Insider Sold Shares Worth $3,600,830, According to a Recent SEC Filing
|
MT
| |
11-06 |
United Therapeutics Insider Sold Shares Worth $3,488,423, According to a Recent SEC Filing
|
MT
| |
11-05 |
United Therapeutics Insider Sold Shares Worth $9,157,821, According to a Recent SEC Filing
|
MT
| |
11-04 |
United Therapeutics Insider Sold Shares Worth $3,554,592, According to a Recent SEC Filing
|
MT
| |
11-03 |
United Therapeutics Corporation Announces First Transplant in Expands Clinical Trial of UKidney in Patients with End-Stage Renal Disease
|
CI
| |
31/10/25 |
United Therapeutics Insider Sold Shares Worth $3,538,949, According to a Recent SEC Filing
|
MT
| |
30/10/25 |
United Therapeutics Insider Sold Shares Worth $4,953,760, According to a Recent SEC Filing
|
MT
| |
29/10/25 |
Tranche Update on United Therapeutics Corporation's Equity Buyback Plan announced on July 30, 2025.
|
CI
| |
29/10/25 |
United Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
|
CI
| |
29/10/25 |
Earnings Flash (UTHR) United Therapeutics Posts Q3 EPS $7.16, vs. FactSet Est of $6.96
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
